| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 69339-0229-50 | 69339-0229 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov 7, 2024 | In Use | |
| 43598-0426-60 | 43598-0426 | Bortexomib | Bortezomib | 3.5 mg/1 | Chemotherapy | Proteasome Inhibitor | 26S | Intravenous, Subcutaneous | Jul 26, 2022 | In Use | |
| 00054-0481-13 | 00054-0481 | Everolimus | Everolimus | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Feb 12, 2021 | In Use | |
| 50268-0427-12 | 50268-0427 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Aug 24, 2017 | In Use | |
| 00173-0847-08 | 00173-0847 | Dabrafenib | Tafinlar | 75.0 mg/1 | Chemotherapy | Enzyme Inhibitor | BRAF | Oral | Jun 10, 2013 | May 31, 2018 | No Longer Used |
| 47335-0929-72 | 47335-0929 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 81298-3890-01 | 81298-3890 | Eribulin Mesylate | Eribulin Mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Jul 22, 2024 | In Use | |
| 00093-7474-89 | 00093-7474 | Capecitabine | Capecitabine | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 7, 2014 | In Use | |
| 54868-5350-04 | 54868-5350 | Temozolomide | Temodar | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 7, 2005 | In Use | |
| 00078-0566-51 | 00078-0566 | Everolimus | Afinitor | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 31, 2009 | In Use | |
| 69945-0450-05 | 69945-0450 | sodium iodide, i-131 | Sodium Iodide I-131 | 5.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct 27, 2015 | Jul 1, 2018 | No Longer Used |
| 42388-0023-26 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Apr 25, 2016 | In Use | |
| 71288-0108-06 | 71288-0108 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jun 26, 2020 | In Use | |
| 83703-0562-01 | 83703-0562 | PEMETREXED | PEMETREXED | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | INTRAVENTRICULAR | Aug 18, 2022 | In Use | |
| 00085-1425-04 | 00085-1425 | Temozolomide | Temodar | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 11, 1999 | In Use | |
| 42388-0023-57 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 9, 2023 | In Use | |
| 25021-0245-04 | 25021-0245 | Docetaxel Anhydrous | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 15, 2017 | In Use | |
| 42388-0025-26 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Apr 25, 2016 | In Use | |
| 00527-1781-14 | 00527-1781 | Temozolomide | Temozolomide | 180.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2016 | May 24, 2018 | In Use |
| 44567-0530-01 | 44567-0530 | cisplatin | Cisplatin | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Apr 5, 2019 | In Use | |
| 00409-0201-27 | 00409-0201 | DOCETAXEL ANHYDROUS | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sep 11, 2013 | Jan 31, 2017 | In Use |
| 59923-0721-60 | 59923-0721 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Mar 1, 2020 | In Use | |
| 68001-0282-25 | 68001-0282 | Gemcitabine Hydrochloride | Gemcitabine Hydrochloride | 38.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 23, 2016 | Aug 1, 2021 | No Longer Used |
| 48433-0049-03 | 48433-0049 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 10, 2026 | In Use | |
| 00069-0298-60 | 00069-0298 | Glasdegib | Daurismo | 25.0 mg/1 | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Oral | Dec 10, 2018 | In Use |
Found 12611 results — Export these results
Home